NDAORALTABLET
Approved
Aug 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LERITINE (anileridine hydrochloride) is an oral synthetic opioid analgesic approved in 1957 for pain management. It is a small-molecule narcotic pain reliever structurally related to meperidine. The drug works by binding to opioid receptors in the central nervous system to provide analgesia.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial teams are likely focused on managed transition and retention strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LERITINE offers limited career growth opportunities given its LOE-approaching lifecycle and zero active job postings. Career value lies primarily in operational efficiency, regulatory maintenance, and portfolio management experience rather than high-visibility brand building or innovation.
Brand Manager (legacy portfolio)Regulatory Affairs Specialist
Worked on LERITINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.